Skip to main content
. 2011 Aug 11;83(10):1841–1848. doi: 10.1002/jmv.22173

Table IV.

Secondary Symptoms With Reference to Virus Detected

Symptomsa Percentage of infected patients
Influenza HRSV HRV HAdV HMPV HPIV HBoV HCoV
Coryza 87.3 76.0 78.7 92.3 81.3 77.8 70.0 89.5
Sore throat 73.0 44.0 72.3 92.3 62.5 66.7 60.0 68.4
Fatigue 73.0 52.0 66.0 92.3 68.8 77.8 50.0 57.9
Headache 70.6 48.0 55.3 53.9 37.5 55.6 40.0 52.6
Myalgia 56.9 32.0 42.6 46.2 31.3 66.7 40.0 26.3
Conjunctivitis 18.6 12.0 14.9 15.4 12.5 11.1 0.0 26.3
Emesis 16.7 12.0 19.1 30.8b 12.5 0.0 10.0 31.6d
Abdominal pain 17.6 20.0 27.7e 30.8b 18.8 0.0 10.0 15.8
Respiratory hindrance 7.8 16.0 8.5 15.4 12.5 11.1 0.0 0.0
Diarrhea 9.8 4.0 8.5 30.8b 16.7 11.1 20.0c 5.3
Clues of pneumonia 2.5 12.0 2.1 15.4 18.8 11.1 10.0 5.3

HRSV, human respiratory syncytial virus; HRV, human rhinovirus; HAdV, human adenovirus; HMPV, human metapneumovirus; HPIV, human parainfluenza virus; HBoV, human bocavirus; HCoV, human coronavirus.

a

Complete clinical data available for 85% of positive cases.

b

RR: 3.312, 95%CI: 2.238–4.901.

c

RR 2.420, 95%CI 1.461–4.009.

d

RR 2.399, 95%CI 1.123–5.128.

e

RR: 1.584, 95%CI: 1.162–2.159.